A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

Project: Other project

Project Details

StatusActive
Effective start/end date6/19/206/18/24

Funding

  • Pfizer, Inc.: $2,239,069.42